Todos os estudos
RecrutamentoFASE2INTERVENCIONISTA

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

This study is looking at a new medicine called NS-089/NCNP-02 for boys aged 4 to 14 who have Duchenne muscular dystrophy (DMD). Specifically, it's for boys whose DMD is caused by a genetic change that can be treated by something called 'exon 44 skipping'. The study aims to find out if this new medicine is safe and how well it works. Participants will receive the medicine through a drip (IV infusion) once a week. The study is divided into two parts, with a small group of boys in the first part, and then more boys joining in the second part to gather more information. All participants will be able to walk without help.

Em resumo

Status
Recrutamento
Fase
FASE2
Patrocinador
NS Pharma, Inc.
Meta de inscrição
20
Iniciar
22 de fev de 2024
Conclusão estimada
11 Set 2026

Sobre o que é este estudo?

Duchenne muscular dystrophy (DMD) is a serious genetic condition that causes muscles to become weaker over time. This study is testing a new medicine called NS-089/NCNP-02. The goal of this medicine is to help correct a specific genetic problem in some boys with DMD, which involves 'skipping' a part of their gene called exon 44. By doing this, the hope is to help the body make a more functional dystrophin protein, which is vital for healthy muscles.

This is a 'Phase 2' study, meaning researchers are looking closely at how safe the medicine is and starting to see if it has a positive effect. It's also 'open-label', which means both the patients and the doctors will know they are receiving the study medicine. The medicine will be given to boys aged 4 to 14 who can still walk on their own.

The study is important because it could potentially offer a new treatment option for boys with DMD who have this specific genetic change. Finding effective treatments is a crucial step towards improving the lives of individuals living with this challenging condition.

Pontos principais

  • This study is testing an experimental medicine (NS-089/NCNP-02) for DMD.
  • It's for boys aged 4-14 with a specific genetic change (exon 44 skipping) who can walk unassisted.
  • The medicine is given weekly through a drip.
  • The study aims to understand the medicine's safety and effectiveness.
  • Participation involves regular hospital visits for assessments and treatment.

Quem pode ser elegível?

To join this study, boys must be between 4 and 14 years old. They need to have a confirmed diagnosis of Duchenne muscular dystrophy (DMD) caused by a specific genetic change (mutation) that can be treated by 'exon 44 skipping'. It's also important that they can walk by themselves without any walking aids and can complete a specific walking test quickly.

Participants must have been on a steady dose of steroid medication for at least three months before starting the study and expect to continue that dose throughout. There are also some reasons why someone might not be able to join. For example, if they have certain heart problems, have used particular medications or other experimental treatments recently, or have had surgery in the last three months.

They also can't have participated in a previous study of this exact medicine (NS-089/NCNP-02) or received other similar 'exon skipping' treatments in the past year. There are other criteria too, so the study team will check everything carefully.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Is the boy between 4 and 14 years old?
  2. Does he have Duchenne muscular dystrophy with an 'exon 44 skipping' genetic change?
  3. Can he walk on his own without any walking aids?
  4. Has he been on a stable dose of steroid medication for at least 3 months?
  5. Has he avoided certain other medications or experimental treatments recently?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, the study involves weekly visits to receive the medicine, NS-089/NCNP-02, through a drip into a vein (IV infusion). The total duration of your involvement will depend on which part of the study you join.

Before treatment starts, there will be screening visits to ensure you meet all the requirements. During the study, you'll have regular check-ups, assessments of your muscle strength and movement (like walking tests), and possibly blood tests to see how the medicine is affecting you. All these visits and tests are designed to monitor your health and how the medicine is working. The study is divided into two parts, so some participants will be involved for longer than others.

Riscos e benefícios potenciais

Participating in a clinical trial may offer potential benefits, such as access to a new treatment that isn't widely available. However, there are also potential risks, as the medicine is still being studied, and not all side effects or benefits are fully known. You might experience side effects, some of which could be unexpected. It's important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (25)

  • Children's Hospital Colorado
    Código postal verificado
    Aurora, Estados Unidos· Recrutamento
  • Rare Disease Research, LLC - FL
    Código postal verificado
    Kissimmee, United States· Recrutamento
  • Pesquisa de Doenças Raras
    Código postal verificado
    Atlanta, Estados Unidos· Recrutamento
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Código postal verificado
    Chicago, Estados Unidos· Recrutamento
  • University of Kansas Medical Center (KUMC)
    Código postal verificado
    Kansas City, Estados Unidos· Recrutamento
  • Cincinnati Children's Hospital Medical Center
    Código postal verificado
    Cincinnati, Estados Unidos· Recrutamento
  • O Hospital Infantil da Filadélfia (CHOP)
    Código postal verificado
    Filadélfia, Estados Unidos· Recrutamento
  • University of Pittsburgh School of Medicine
    Código postal verificado
    Pittsburgh, Estados Unidos· Recrutamento
  • UT Southwestern/Children's Health
    Código postal verificado
    Dallas, Estados Unidos· Recrutamento
  • Virginia Commonwealth University Health System
    Código postal verificado
    Richmond, United States· Recrutamento
  • Hospital Infantil de Perth
    Código postal verificado
    Nedlands, Austrália· Ainda não recrutando
  • Alberta Children's Hospital
    Código postal verificado
    Calgary, Canadá· Ainda não recrutando

Perguntas frequentes

What is Duchenne muscular dystrophy (DMD)?

DMD is a genetic condition that causes muscles to get weaker over time, making it harder to move around.

What does 'exon 44 skipping' mean?

It's a way the new medicine tries to fix a specific error in the DNA of some boys with DMD, helping their bodies make a vital muscle protein.

Como o medicamento será administrado?

The medicine, NS-089/NCNP-02, will be given through a drip into a vein (an IV infusion) once a week.

Can I join if I use a wheelchair?

No, this study is specifically for boys who can still walk independently without any help.

What is a 'Phase 2' study?

Phase 2 studies are designed to see if a new medicine is safe and starts to show a positive effect, building on earlier safety tests.

Como saber mais

Trial info

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy …" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.